OBX
Obsidian Therapeutics, Inc. (OBX)
Healthcare • NASDAQ • $18.45-4.10%
- Symbol
- OBX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $18.45
- Daily Change
- -4.10%
- Market Cap
- $1.23B
- Trailing P/E
- N/A
- Forward P/E
- -9.34
- 52W High
- $49.97
- 52W Low
- $14.57
- Analyst Target
- $42.50
- Dividend Yield
- N/A
- Beta
- 2.64
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform t…
Company websiteResearch OBX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.